The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder
Randomized, Open Label Study of Dasatinib (100mg qd) vs. High-Dose Imatinib (600mg) in Patients With Chronic Phase CML Who Have Had Suboptimal Response After 3-18 Months of Therapy With Imatinib (400mg)
Sponsor: Pusan National University Hospital
This observational or N/A phase trial investigates Chronic Myeloid Leukemia and is currently ongoing. Pusan National University Hospital leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Available
-
Jul 2024 — Sep 2024 [monthly]
Available
-
Jan 2021 — Jul 2024 [monthly]
Available
-
Apr 2018 — Jan 2021 [monthly]
Available
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Available NA
Status: Unknown Status → Available
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pusan National University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.